Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Artificial intelligence may help predict response to immune checkpoint blockade in patients with metastatic melanoma
Scientists studied the drug, BO-112, using lab dish experiments and a mouse model of melanoma.
After being diagnosed with internal melanoma, Gail decided to undergo a clinical trial of an experimental combination.
After being diagnosed with a rare type of melanoma, Amy Jardon did research and created a Facebook group for acral melanoma patients.
Tumors with large numbers of genetic mutations may be especially susceptible to treatment with immunotherapy.
Recent studies on acral melanoma presented at the 2020 Melanoma Research Alliance Scientific Retreat are showing promising findings.
BO-112 helped make tumor cells more vulnerable to immunotherapy, offering a possible treatment route for hard-to-treat cancers.
The Melanoma Research Alliance is powering a revolution in melanoma research.
Researchers are hard at work developing meaningful improvements through next-generation treatments that could improve patient outcomes.
After being melanoma-free for five years in 2000, McGowan began a 4,250-mile adventure from Oregon to the Atlantic Ocean in Virginia.
Doctors aren’t properly trained to detect melanoma in patients with Black skin.
The most aggressive type of skin cancer may respond to immunotherapy.
Melanoma Research Alliance Board member Ellen Davis discusses how a sign at a dermatologist’s office convinced her to see a dermatologist.
The new tests, which screen for metastasis, could someday replace skin biopsies.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.